What will the Transparency Council do on March 21?
AOTMiT: The Transparency Council will evaluate drugs, incl. for drug-resistant depression and multiple myeloma
Published March 16, 2022 08:27
Źródło: AOTMiT
The agenda includes:
Preparation of drug assessment positions:
• Cresemba (isavuconazolum) in the indications: treatment of invasive aspergillosis in adult patients for whom voriconazole therapy is not indicated; treatment of mucormycosis in patients for whom treatment with amphotericin B is not indicated,
• Spravato (esketaminum) as part of the drug program: "Treatment of patients with drug-resistant depression with esketamine (ICD-10: F33.1, F33.2)",
• Darzalex (daratumumabum) as part of the B.54 drug program. "Treatment of patients with refractory or relapsed multiple myeloma (ICD10 C90.0).
Preparation of an opinion on the draft health policy program of a local government unit "Program of early detection of hearing and vision defects among children aged 6 years in the Świebodzin commune for the years 2022-2024".
Source: AOTMiT
